REDWOOD CITY, Calif., Jan. 4 /PRNewswire/ -- Codexis, Inc., a privately held biosciences company, today announced that Robert S. Breuil has been named Senior Vice President and Chief Financial Officer, reporting directly to Alan Shaw, Ph.D., Codexis’ President and Chief Executive Officer. In his new position, Mr. Breuil will have responsibility for all company financial operations, investor relations, information technology and facilities.
Dr. Shaw commented, “We are delighted to be welcoming Robert to the senior management team. He brings to Codexis extensive knowledge and experience in the financial management of life sciences organizations. Robert has a proven track record of identifying and maximizing shareholder value, and we expect that he will make immediate contributions to the Company as we continue our rapid expansion in high growth markets.”
Prior to joining Codexis, Mr. Breuil was Chief Financial Officer and Vice President, Corporate Development at Aerogen, Inc. from 2002 to 2005. Aerogen was a publicly traded life sciences company until its acquisition by Nektar Therapeutics in late 2005. Previously, Mr. Breuil held a number of senior financial management positions at ALZA Corporation from 1994-2002, most recently as Controller of ALZA Pharmaceuticals. ALZA Corporation was acquired by Johnson & Johnson in 2001, and Mr. Breuil was retained to oversee and facilitate the smooth transition of commercial operations to various J&J companies.
Mr. Breuil received a Bachelor of Science degree in electrical engineering from the U.S. Naval Academy in 1983 and served on active duty as an aviator with the U.S. Navy from 1983-1991. He received an MBA degree from the Stanford University Graduate School of Business in 1993.
About Codexis, Inc.
Codexis is a privately held biosciences company applying proprietary synthetic chemistry technologies to create improved versions of small molecule therapeutics. Codexis’ technology enables novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing. Application of the company’s proprietary protein and strain engineering platform can also generate new intellectual property opportunities for pharmaceutical manufacturers, which may extend the drug product lifecycle. Codexis has more than 12 strategic alliances and more than 20 products and processes in development internally and at leading worldwide life sciences companies. Codexis, Inc. began operations as an independent company in 2002.
Codexis Technology Background
The Codexis MolecularBreeding(TM) protein and strain engineering technology platform creates superior biological catalysts -- either enzymes or fermentation strains -- crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines, dramatically improve existing manufacturing processes and increase chemical development productivity. Codexis estimates that its platform technology can reduce cost of goods by 35% - 65% and capital expenditures by over 25%. In addition, this platform technology can create new patents, which can help extend the lifetime of drug products.
Codexis’ partnerships draw upon the company’s expertise and track record in applying its proprietary technology to high-value pharmaceutical products to improve their purity profile and reduce manufacturing time, cost and waste. Codexis has over a dozen partnerships with leading worldwide proprietary and generic pharmaceutical manufacturers.
Codexis’ platform technology begins with the selection of genes or genomes with DNA sequence diversity. These gene or genomic variants are then subjected to a proprietary technique that recombines, or “shuffles,” the DNA. The resulting library encoding for novel enzymes or strains is screened for those possessing desirable and improved properties. This process is repeated several times until the resulting enzymes or strains meet or exceed the target performance.
Codexis is a trademark of Codexis, Inc. Contact: Codexis, Inc. Tassos Gianakakos Sr. Vice President, Business Development T. +1-650-298-5423 F. +1-650-298-5449 tassos.gianakakos@codexis.com Media: Tricia Morsch Burns McClellan 212-213-0006 tmorsch@burnsmc.com
Codexis, Inc.
CONTACT: Tassos Gianakakos, Sr. Vice President, Business Development, ofCodexis, Inc., +1-650-298-5423, F. +1-650-298-5449, ortassos.gianakakos@codexis.com; or Media: Tricia Morsch of Burns McClellan,+1- 212-213-0006 or tmorsch@burnsmc.com, for Codexis, Inc.
Web site: http://www.codexis.com/
